Eltrombopag
Eltrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by promoting the growth and maturation of megakaryocytes, the bone marrow cells responsible for creating platelets. It is primarily used to treat conditions associated with low platelet counts, such as chronic immune thrombocytopenia (ITP), severe aplastic anemia, and thrombocytopenia in patients with chronic hepatitis C.
A platelet-boosting medication for conditions causing low blood platelet counts.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- B02BX05
- RxNorm
- 711942
- Generic
- Eltrombopag
- Class
- atc-b02
- Brands
- Alvaiz, Promacta
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet, suspension
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Eltrombopag is used to treat chronic immune thrombocytopenia (ITP) in patients who have not responded adequately to other treatments, severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C infection.
Eltrombopag binds to the transmembrane domain of the human TPO receptor (cMpl), triggering signaling cascades that stimulate megakaryocyte proliferation and differentiation, ultimately leading to increased platelet production.
Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after foods, supplements, or antacids containing polyvalent cations. Regular blood monitoring is required due to risks of liver problems, bone marrow changes, and potential increased risk of blood clots. Treatment should be avoided in patients with known risk factors for thrombosis.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy